Mast cell leukemia
| Acute mast cell leukemia | |
|---|---|
| Peripheral blood showing mast cell leukemia. | |
| Specialty | Hematology and oncology |
Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de novo but can, rarely, evolve from transformation of chronic myeloid leukemia into the more aggressive acute myeloid leukemia. In a small proportion of cases, acute mast cell leukemia may evolve from a more progressive form of systemic mastocytosis. In addition to meeting the diagnostic criteria for systemic mastocytosis, diagnosis of mast cell leukemia requires at least 20% atypical, immature mast cells in a bone marrow smear. Both the 2022 fifth edition of the WHO classification and the 2022 International Consensus Classification (ICC), which replaced the revised fourth edition of 2016, retain this threshold; the ICC additionally permits diagnosis on a bone marrow biopsy where the aspirate smear is inadequate. MCL can be further classified as leukemic (at least 10% atypical immature circulating mast cells in peripheral blood) or aleukemic (less than 10% circulating MCs), but the importance of this distinction is debated, and the ICC instead recommends reporting any circulating mast cells because of their adverse prognostic significance.